secwatch.observer — SEC 8-K summary
======================================

Issuer:     Valion Bio, Inc. (VBIO)
CIK:        0001787740
Form:       8-K
Filed at:   2025-11-14T23:59:59+00:00
Accession:  0001437749-25-035208
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 7.01, 2.05, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tivic Health winds down ClearUP consumer biz; Q3 net loss $2.6M
---------------------------------------------------------------

- Q3 revenue $146K (+16% YoY); gross loss $145K from $230K inventory reserve for ClearUP exit.
- Net loss $2.6M vs $1.4M in Q3 2024; operating expenses rose to $2.3M on biopharma costs.
- ClearUP wind down: $347K charge incurred, $20-50K more expected; minimal revenue until approval.
- Transferred two INDs for Entolimod (neutropenia, cancer); cell line verification for cGMP completed.
- Cash $3.5M; $3.5M available via preferred equity; no debt.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787740/000143774925035208/0001437749-25-035208-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787740/000143774925035208/tivc20250909_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-035208

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer